1st April, 2019: InnAccel has launched SAANS - the world’s first infrastructure-independent, portable, neonatal CPAP system. It is built to provide breathing support to critically ill neonates with Respiratory Distress Syndrome (RDS) in resource-poor settings and during transportation. Developed by Coeo Labs, a division of InnAccel, SAANS is the only CPAP device with multiple power options, including a patented manual mode. SAANS requires minimal skill to use, and will help reduce one of India’s major causes of infant mortality. The device has been conceptualized in collaboration with Dr. Kristian Olson (USA) and Dr. Data Santorino
(Uganda) of the Consortium of Affordable Medical Technologies (CAMTech), and has been designed,
engineered, and manufactured indigenously, a shining example of Make in India. This innovation has received multiple Indian and international awards including American Society of Mechanical Engineers
Global iShow Finalist (2017), 3M Young Innovator award (2016), FICCI Healthcare award (2015), and the
Tata Social Enterprise award (2015).
Speaking on the revolutionary product, Siraj Dhanani, Founder, CEO, InnAccel Technologies, said, “Respiratory Distress Syndrome (RDS) is a common breathing disorder in premature babies in India,
causing 150,000 deaths annually. And, one-third of these deaths occur while the infants are being
transported to an NICU. In rural areas where facilities are limited, many babies don’t even get the
opportunity to receive CPAP treatment. Also, CPAP devices that are currently available in the market are
not just expensive, but also designed only for use in the NICU. We wanted to address this gap with our
unique offering. SAANS is an India-specific solution that resolves this critical issue of non-availability of
CPAP in non-NICU settings and during transport to a NICU.We are truly grateful to the Government for
funding the SAANS project through BIRAC and Department of Biotechnology, which would not have
turned into a reality without their support”.
“